Lymphoma Research Foundation Publishes White Paper to Outline Key Issues Discussed During Second Oral Therapies Workshop
In October 2017, The Lymphoma Research Foundation (LRF) convened its second Adherence and Oral Therapies in Lymphoma and CLL Workshop with a diverse faculty to explore and encourage dialogue among experts in the field on areas of future investigation, including an overview of the epidemiology and types of nonadherence; the need to research polypharmacy (use of multiple drugs simultaneously), adherence and collaborative healthcare models; and the experience of clinicians and researchers working in chronic myeloid leukemia (CML) over the past decade following the introduction of oral tyrosine kinase inhibitors.
The Foundation developed the White Paper, Adherence and Oral Therapies in Lymphoma and CLL as its latest contribution to the ongoing discussion on the growing importance of the role of oral therapies in the treatment of cancer. The paper highlights key discussion items from the Workshop, including the ways in which nonadherence may contribute to poor treatment outcomes and lead to increased health care utilization.
Download the White Paper today.